% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Cetindag:286094,
      author       = {Cetindag, Arda C and Schipke, Carola G and Esselmann,
                      Hermann and Kruse, Niels and Wiltfang, Jens and Schneider,
                      Anja and Fliessbach, Klaus and Miklitz, Carolin and Maier,
                      Franziska and Buerger, Katharina and Janowitz, Daniel and
                      Ewers, Michael and Stöcklein, Sophia and Perneczky, Robert
                      and Rauchmann, Boris Stephan and Kurz, Carolin and Teipel,
                      Stefan and Kilimann, Ingo and Goerss, Doreen and Laske,
                      Christoph and Sodenkamp, Sebastian and Najafpour, Elham and
                      Wagner, Michael and Roeske, Sandra and Frommann, Ingo and
                      Stark, Melina and Brosseron, Frederic and Ramirez, Alfredo
                      and Kleineidam, Luca and Priller, Josef and Spruth, Eike
                      Jakob and Gemenetzi, Maria and Altenstein, Slawek and
                      Düzel, Emrah and Glanz, Wenzel and Incesoy, Enise I and
                      Butryn, Michaela and Bauer, Chris and Jessen, Frank and
                      Peters, Oliver},
      title        = {{P}lasma {GFAP} outperforms {CSF} {GFAP} in detecting
                      amyloid pathology and is associated with increased risk of
                      clinical progression in early {A}lzheimer's disease.},
      journal      = {The journal of prevention of Alzheimer's disease},
      volume       = {13},
      number       = {5},
      issn         = {2274-5807},
      address      = {[Paris]},
      publisher    = {Elsevier Masson SAS},
      reportid     = {DZNE-2026-00390},
      pages        = {100544},
      year         = {2026},
      abstract     = {Early and accurate detection of Alzheimer's disease (AD) is
                      essential for timely intervention and development of
                      disease-modifying treatments. The DZNE-Longitudinal
                      Cognitive Impairment and Dementia Study (DELCODE) provides a
                      deeply phenotyped cohort covering preclinical and early
                      clinical stages, including subjective cognitive decline
                      (SCD) and mild cognitive impairment (MCI). Astrocyte
                      reactivity and its biomarkers, particularly glial fibrillary
                      acidic protein (GFAP), have gained increasing attention in
                      AD research; however, the relationship between GFAP and
                      amyloid in early disease, as well as its potential
                      prognostic value beyond its association with amyloid status,
                      remains insufficiently understood.To evaluate the
                      performance of CSF and plasma GFAP across early disease
                      stages, compare these measures according to amyloid status,
                      and assess the prognostic value of GFAP for clinical
                      progression across diagnostic stages during longitudinal
                      follow-up.This study used data from the multicenter DELCODE
                      cohort in Germany, including participants with available
                      plasma and/or CSF samples and standardized clinical,
                      cognitive, imaging, and biomarker assessments.GFAP
                      concentrations in plasma and CSF were quantified using
                      validated immunoassay platforms. Standard CSF AD biomarkers
                      and ApoE genotype were measured using established assays.
                      Amyloid status was defined by the CSF Aβ42/40 ratio.
                      Longitudinal follow-up occurred annually for up to ∼10
                      years, with clinical conversion determined according to
                      NIA-AA criteria.Plasma and CSF GFAP increased across the AD
                      continuum, with higher levels in MCI and AD (p < 0.001).
                      Plasma GFAP showed a stronger association with amyloid
                      status than CSF GFAP across all groups. In MCI, plasma GFAP
                      combined with age and ApoE4 yielded an AUC of 0.87. Elevated
                      plasma GFAP predicted increased risk of conversion to MCI
                      (HR = 2.19, p < 0.001; adjusted HR = 1.70, p = 0.0056) and
                      AD dementia (HR = 3.5; adjusted HR = 2.49 both p <
                      0.001).Plasma GFAP is a sensitive, minimally invasive
                      biomarker with diagnostic relevance for amyloid detection
                      and prognostic relevance for clinical progression in early
                      AD.},
      keywords     = {Alzheimer’s disease (Other) / Blood biomarkers of
                      Alzheimer’s disease (Other) / Cerebrospinal fluid (CSF)
                      (Other) / Glial fibrillary acidic protein (GFAP) (Other) /
                      Mild cognitive impairment (Other) / Subjective memory
                      decline (Other)},
      cin          = {AG Peters / AG Wiltfang / AG Schneider / Patient Studies
                      (Bonn) / Clinical Research (Munich) / AG Dichgans / AG
                      Teipel / AG Gasser / ICRU / AG Wagner / AG Heneka / AG
                      Priller / AG Düzel / AG Jessen},
      ddc          = {610},
      cid          = {I:(DE-2719)5000000 / I:(DE-2719)1410006 /
                      I:(DE-2719)1011305 / I:(DE-2719)1011101 / I:(DE-2719)1111015
                      / I:(DE-2719)5000022 / I:(DE-2719)1510100 /
                      I:(DE-2719)1210000 / I:(DE-2719)1240005 / I:(DE-2719)1011201
                      / I:(DE-2719)1011303 / I:(DE-2719)5000007 /
                      I:(DE-2719)5000006 / I:(DE-2719)1011102},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41905188},
      pmc          = {pmc:PMC13054424},
      doi          = {10.1016/j.tjpad.2026.100544},
      url          = {https://pub.dzne.de/record/286094},
}